Peptide Industry advanced
Peptide Regulatory Approval Pathways
Navigating the regulatory pathways for peptide drug approval in major markets.
By Encyclopeptide Editorial | 1 min read
regulatory approval fda ema
Overview
Peptide drugs follow specific regulatory pathways that differ from small molecules and large biologics.
US Pathways
- NDA: New Drug Application for novel peptides
- ANDA: Abbreviated NDA for generic peptides
- 505(b)(2): Hybrid application using literature data
- BLA: For recombinant peptide biologics
European Pathways
- Centralized procedure: EMA approval for EU-wide marketing
- National procedure: Single-country approval
- Biosimilar pathway: For recombinant peptide follow-ons
Key Requirements
- Comprehensive CMC documentation
- Comparability studies for generics
- Immunogenicity assessment
- Clinical endpoint or bioequivalence studies
References
- Source: ENCP Peptide Database
- Category: Peptide Industry
Test Your Knowledge
Reinforce what you learned about Peptide Regulatory Approval Pathways with interactive quizzes on Wikipept.
Take a Quiz on Wikipept